CN101112494B - Medicine for treating coronary disease and method for preparing the same - Google Patents
Medicine for treating coronary disease and method for preparing the same Download PDFInfo
- Publication number
- CN101112494B CN101112494B CN200610032041A CN200610032041A CN101112494B CN 101112494 B CN101112494 B CN 101112494B CN 200610032041 A CN200610032041 A CN 200610032041A CN 200610032041 A CN200610032041 A CN 200610032041A CN 101112494 B CN101112494 B CN 101112494B
- Authority
- CN
- China
- Prior art keywords
- medicine
- gram
- heart disease
- coronary heart
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a drug for treating coronary heart disease, which takes suberect spatholobus stem, omoto nipponlily, grassleaf sweelflag rhizome, Szechwan Chinaberry fruit and danshenroot as the raw materials; the medicines are smashed after drying according to the different characteristics of the Chinese herbal medicines and are prepared in proportion after the boiling, extraction and other pretreatments, finally the medicines are prepared into the powder or capsule by maturation and sterilization. The formulation of the present invention has significant treatment effects andthe functions of activating blood circulation, removing blood stasis, improving the cardiac muscle blood supply insufficiency and enhancing the contraction force of cardiac muscle, which can reduce the times of the coronary heart disease attack, shorten the duration time, increase the blood flow of coronary artery, improve the peripheral circulation, improve the cardiac muscle blood supply insufficiency, expand the coronary artery, inhibit the platelet aggregation, reduce the thrombosis, increase the nutrition of the myocardial cells, reduce the oxygen consumption of the myocardial cells, delay the senescence and death of the myocardial cells and prevent the occurrence of heart failure.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of coronary heart disease, is the Chinese patent medicine of feedstock production with the Chinese herbal medicine specifically, the invention still further relates to the preparation method of this medicine.
Background technology
Coronary heart disease is commonly encountered diseases, the frequently-occurring disease of serious harm human health, and the coronary heart disease number rises year by year in the world at present, and the case fatality rate height is one of human three big diseases of serious harm.Relapse of coronary disease rate height, instability, the case fatality rate height, at the bottom of the cure rate, angina pectoris is a coronary insufficiency, the clinical syndrome that ischemia that cardiac muscle is sharply temporary transient and anoxia cause causes heart failure and death at last.
Both at home and abroad to the primary disease Drug therapy, run into following thorny problem at present:
1. dosage is difficult to grasp, and side effect is big.
2. drug effect is not lasting, easily produces drug resistance.
3. existing treatment coronary heart disease medicine is with damaging the part internal organs long afterwards.
Though the Chinese patent medicine of some treatment coronary heart disease is also arranged, because effect is not fairly obvious, the patient still has to depend on some Western medicine, as medicines such as Folium Digitalis Purpureae, heart tonifying glycoside.
Summary of the invention
The object of the present invention is to provide a kind of have invigorate blood circulation, blood stasis dispelling, improve deficiency myocardial blood supply, strengthen myocardial contraction, reduce the coronary heart attack number of times and shorten the medicine of persistent period; It is to improving blood viscosity, blood fat reducing, and blood pressure regulation variation etc. all has the significance meaning.
Another object of the present invention provides the preparation method of this therapeutic drug of coronary heart disease.
Solution of the present invention is based on motherland's medical science to coronary heart disease and pathogenetic understanding of complication and Therapeutic Principle, achieve with reference to modern pharmacological research, from motherland's medical treasure-house, filter out excessive kidney yin, enrich blood, QI invigorating void, blood stasis dispelling blood, dredge the meridian passage, utilize natural plant, by the theory of Chinese medical science prescription, skim the cream off milk, blood circulation promoting and blood stasis dispelling increases coronary flow, improves peripheral circulation, improve deficiency myocardial blood supply, coronary artery dilator, anti-blood is pulled gathering for a short time, reduces the thrombosis degree, increase myocardial cell nutrition, reduce myocardial oxygen consumption, it is old and feeble and dead to delay myocardial cell, and prophylaxis of heart failure takes place.
Medicine of the present invention is made (consumption is a weight portion) by following component:
Caulis Spatholobi 18-60, Rohdea japonica Roth 5-10, Rhizoma Acori Graminei 6-20, Fructus Toosendan 5-12, Radix Salviae Miltiorrhizae 10-20.
Formula optimization weight (part) ratio range of preparation medicine of the present invention is:
Caulis Spatholobi 20-35, Rohdea japonica Roth 5-8, Rhizoma Acori Graminei 10-12, Fructus Toosendan 5-10, Radix Salviae Miltiorrhizae 10-15.
The optimum weight of medicine of the present invention (part) proportioning is:
Caulis Spatholobi 35, Rohdea japonica Roth 7, Rhizoma Acori Graminei 12, Fructus Toosendan 9, Radix Salviae Miltiorrhizae 12.
With above-mentioned each component, make medicine production method of the present invention and be:
1. get Caulis Spatholobi earlier and carry out ripening under 100 ℃ of-105 ℃ of temperature, the extracting solution that removes slag is condensed into cream.
2. get Rhizoma Acori Graminei, Fructus Toosendan, Radix Salviae Miltiorrhizae, the air-dry back pulverizing of Rohdea japonica Roth 120 order fine powders.
3. get the Caulis Spatholobi runny plaste and above-mentioned medicated powder is mixed, make loose powder.
4. above-mentioned powder component was carried out the ripening sterilization treatment 10-30 minute, the powder medicine of the coronary heart disease that can obtain medical treatment after by described mixed under 100 ℃ of-110 ℃ of temperature.
5. encapsulated or powder is vacuum-packed under aseptic basis.
The ripening disinfecting action here is to adopt step type cooling ripening sterilization, and temperature is raised to 110 ℃ rapidly, and segmentation thereafter drops to 100 ℃, and the ripening sterilization time is 10-30 minute.
Powder after the maturation process also can be reprocessed into similar ball shape type, honey pill agent for example, and need add an amount of binding agent this moment again, as Mel, compression moulding under negative pressure, dry and pack with vacuum mode.
No Fructus Toosendan can replace with Rhizoma Corydalis in the above-mentioned prescription.
A key character of the present invention is to contain rich nutrient contents in the medicament, and circulation of qi promoting is enriched blood, and the characteristics of enriching blood are the inaccessible characteristics of enriching blood of other medicine of enriching blood.Rohdea japonica Roth in the side (Liliaceae) nature and flavor hardship, cold, heart tonifying, diuresis; Caulis Spatholobi (all sorts of flowers mucuna) nature and flavor are puckery, sour, heart tonifying, enrich blood, collateral dredging; Rhizoma Acori Graminei nature and flavor suffering, temperature, the refreshment of having one's ideas straightened out; Fructus Toosendan nature and flavor hardship, cold, promoting the circulation of QI to relieve pain; Radix Salviae Miltiorrhizae nature and flavor hardship, be slightly cold blood circulation promoting and blood stasis dispelling.
Another important feature of the present invention is dredge the meridian passage, blood circulation promoting and blood stasis dispelling, and to the endocrine model of nerve---body fluid or nerve---of heart failure, intervene heart failure take place and evolution in---the unify treatment of feritin---angiotensin---aldosterone system of humoral system, especially sympathetic nervous system has all obtained great success by the activated nerve of transition.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
1 the present invention uses natural plant to be raw material, and each component meets the pharmaceutical control law regulation, utilizes the comprehensive function treatment coronary heart disease of the Chinese medicine of respectively distinguishing the flavor of, no chemical element, nontoxic.
2. the present invention need not decoct, and lasting medicine, taking convenience meet the national health law regulation.
3. this invention medicine can use separately, will significantly increase as share effect with other cardiovascular druies, and can significantly eliminate and alleviate other complication, the immunity of enhancing body.
4. medicine of the present invention source is wide, and the medicine valency is cheap, can replace expensive import or home-made cardiovascular medicine, reduces patient's medical expenses.
For showing the therapeutic effect of medicine of the present invention to coronary heart disease, the present invention is through the clinical observation of 300 routine systems, and select medical history, the state of an illness, age, sex, reaching suitable patients with coronary heart disease 118 examples of former Therapeutic Method is that test group, 115 examples are matched group, and all patients all meet the diagnostic criteria of " ischemic heart desease " of World Health Organization's formulation.Wherein, test group man 50 examples, women 68 examples, the age 7---9 years old, the course of disease 3 months---21 years, accompanied with hypertension 30 examples, artrial premature beat 15 examples, ventricular premature contraction 18 examples, coronary heart disease 42 examples, viral myocarditis 10 examples, unknown cause 3 examples; Matched group man 40 examples, women 75 examples, age 7----69 year, the course of disease 3 months----21 years.
Therapeutic Method: test group on former treatment basis, other cardiovascular druies of stopping using, take medicine of the present invention, instructions of taking: 15g/ time, day clothes 3 times can 100g time/day of matched Cor Sus domestica.Matched group is cardiovascular treatment routinely.3 months observation periods, one month one course of treatment, totally three courses of treatment, adopt same procedure regularly to have an electro-cardiogram and coherence check.
The curative effect grade scale: produce effects, subjective symptoms disappears, electrocardiogram recovers normal; Take a turn for the better, subjective symptoms takes a turn for the better, cardiopalmus phenomenon, the more preceding minimizing of premature beat number of times＞50% or more than, electrocardiogram obviously improves; Invalid, after the course of treatment early rich number of times (or cardiopalmus phenomenon) more preceding minimizing＜50% or do not have change, electrocardiogram does not have improvement.
Observed result: two groups of clinical efficacy contrasts are as follows:
The clinical efficacy contrast table
Find out experimental group effect 96 examples (wherein prostatitis 5 examples, hypertension 23 examples) improvement 19 examples, invalid 3 examples, total effective rate 97.5% in the table, be higher than matched group.
The specific embodiment
Take by weighing raw material by following proportioning:
Caulis Spatholobi 35kg, Rohdea japonica Roth 7kg, Rhizoma Acori Graminei 12kg, Fructus Toosendan 9kg, Radix Salviae Miltiorrhizae 12kg.
Production method one is as follows:
1. earlier Caulis Spatholobi is thinly sliced under 100 ℃ of-105 ℃ of temperature and carry out ripening, promptly add decocting in water system and extract twice, remove slag, extracting solution is condensed into cream.
Again with Rohdea japonica Roth, Rhizoma Acori Graminei, Fructus Toosendan, Radix Salviae Miltiorrhizae, be ground into 120 order fine powders.
3. get the Caulis Spatholobi runny plaste and above-mentioned medicated powder is mixed, drying is made loose powder.
With above-mentioned powder component by after the described mixed 110 ℃ of insulations 10 minutes down, cool to 105 ℃ of insulations 5 minutes then, be cooled to 100 ℃ of insulations 15 minutes again, carry out the ripening sterilization and make powder.
5. encapsulated or powder is vacuum-packed under aseptic basis.
Production method two is as follows:
1,2,3 steps are with method one.
With above-mentioned powder component by after the described mixed, be mixed and made into honeyed pill with Mel, compression moulding under negative pressure, dry and pack with vacuum mode.
In above-mentioned prescription and production method,, can replace routine dose 6kg with Rhizoma Corydalis as if no Fructus Toosendan.
Claims (7)
1. a medicine for the treatment of coronary heart disease is characterized in that it is the medicament of being made by the following weight proportion raw material: Caulis Spatholobi 20-35 gram, Rohdea japonica Roth 5-8 gram, Rhizoma Acori Graminei 6-15 gram, Fructus Toosendan 5-10 gram, Radix Salviae Miltiorrhizae 10-20 gram.
2. the medicine of treatment coronary heart disease according to claim 1, wherein the weight proportion of each raw material is: Caulis Spatholobi 25-35 gram, Rohdea japonica Roth 5-8 gram, Rhizoma Acori Graminei 8-12 gram, Fructus Toosendan 5-10 gram, Radix Salviae Miltiorrhizae 10-15 gram.
3. the medicine of treatment coronary heart disease according to claim 1, wherein the weight ratio of each raw material is: Caulis Spatholobi 35 grams, Rohdea japonica Roth 7 grams, Rhizoma Acori Graminei 12 grams, Fructus Toosendan 9 grams, Radix Salviae Miltiorrhizae 12 grams.
4. according to the medicine of claim 1 or 2 or 3 described treatment coronary heart disease, it is characterized in that said medicament is a said dosage form on any pharmaceutics.
5. require the medicine of 5 described treatment coronary heart disease according to claim, it is characterized in that said medicament is capsule, powder or pill.
6. according to the preparation method of the medicine of the described treatment coronary heart disease of claim 5, it is characterized in that: 1. get the Caulis Spatholobi section earlier and under 100 ℃ of-105 ℃ of temperature, add water cure, abandon residue, extracting solution is condensed into cream;
2. get Rohdea japonica Roth, Rhizoma Acori Graminei, Fructus Toosendan, Radix Salviae Miltiorrhizae drying and crushing to 120 order fine powder;
3. get the Caulis Spatholobi runny plaste and above-mentioned medicated powder is mixed, make loose powder;
4. with above-mentioned whole powder components by described mixed,---carry out ripening sterilization treatment 10 under 110 ℃ of temperature---at 100 ℃ and made powder in 30 minutes.
7. according to the preparation method of the medicine of the described treatment coronary heart disease of claim 5, it is characterized in that: 1. 2. 3. with claim 6;
4. above-mentioned whole powder components are pressed described mixed, again with the mixed honeyed pill of Mel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610032041A CN101112494B (en) | 2006-07-28 | 2006-07-28 | Medicine for treating coronary disease and method for preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610032041A CN101112494B (en) | 2006-07-28 | 2006-07-28 | Medicine for treating coronary disease and method for preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101112494A CN101112494A (en) | 2008-01-30 |
| CN101112494B true CN101112494B (en) | 2010-05-12 |
Family
ID=39021123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610032041A Expired - Fee Related CN101112494B (en) | 2006-07-28 | 2006-07-28 | Medicine for treating coronary disease and method for preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101112494B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108403882B (en) * | 2018-04-25 | 2021-06-04 | 四川光大制药有限公司 | Salvia miltiorrhiza composition for treating coronary heart disease and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334121A (en) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | Medicinal composition for restoring cardiac collaterals and its application |
-
2006
- 2006-07-28 CN CN200610032041A patent/CN101112494B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334121A (en) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | Medicinal composition for restoring cardiac collaterals and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101112494A (en) | 2008-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105147847A (en) | Drug composition for benefiting qi and nourishing blood | |
| CN101716242B (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases | |
| CN103071128A (en) | Externally-applied plaster for curing dysmenorrhea | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN101411826A (en) | Internal-use medicament for treating psoriasis | |
| CN103585478B (en) | Chinese medicinal composition for treating hypertension | |
| CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN104258350A (en) | Traditional Chinese medicine preparation for treating sick sinus syndrome and preparation method of traditional Chinese medicine preparation | |
| CN105535390A (en) | Traditional Chinese medicine decoction for treating coronary heart disease and preparation method of traditional Chinese medicine decoction | |
| CN103182008A (en) | Preparation method for traditional Chinese medicine used for stabilizing and reducing blood pressure | |
| CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN104547523A (en) | Medicine for enhancing immunity and preparation method thereof | |
| CN101112494B (en) | Medicine for treating coronary disease and method for preparing the same | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN102266481B (en) | Chinese medicinal preparation for treating chronic cerebral circulation insufficiency | |
| CN101972367A (en) | Traditional Chinese medicine for treating diabetic peripheral neuropathy | |
| CN104117018A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN104127670A (en) | Traditional Chinese medicine decoction for treating arrhythmia | |
| CN104116908A (en) | A traditional Chinese medicine decoction for treating arrhythmia | |
| CN108853340A (en) | A kind of Chinese medicine of nourishing the liver and kidney and preparation method thereof | |
| CN103223107A (en) | Traditional Chinese medicine used for adjusting blood fat and blood pressure, and preparation technology thereof | |
| CN102000267B (en) | Tonic wine | |
| CN104857395A (en) | Medicine for treating qi-deficiency anemia and improving human body immunity and preparation method | |
| CN106606587A (en) | Blood-tonifying body-tranquillizing pharmaceutical composition | |
| CN104940679A (en) | Health preserving capsule for treating diabetes, and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100512 Termination date: 20120728 |